MicroRNA Diagnostics
The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Source: rosettagenomics.com
Companies: Rosetta Genomics
Keep Reading
Most Popular

The hype around DeepMind’s new AI model misses what’s actually cool about it
Some worry that the chatter about these tools is doing the whole field a disservice.

The walls are closing in on Clearview AI
The controversial face recognition company was just fined $10 million for scraping UK faces from the web. That might not be the end of it.

A quick guide to the most important AI law you’ve never heard of
The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.

These materials were meant to revolutionize the solar industry. Why hasn’t it happened?
Perovskites are promising, but real-world conditions have held them back.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.